![[Valid RSS]](images/valid-rss-rogers.png "Valid RSS")
This is a valid RSS feed.
This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.
<content:encoded><![CDATA[
line 170, column 0: (9 occurrences) [help]
<content:encoded><![CDATA[
line 170, column 0: (9 occurrences) [help]
<content:encoded><![CDATA[
line 191, column 0: (2 occurrences) [help]
<figure class="wp-block-gallery has-nested-images columns-default is-cropped ...
line 212, column 0: (6 occurrences) [help]
line 492, column 0: (11 occurrences) [help]
<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:media="http://search.yahoo.com/mrss/" > <channel> <title>International Pharmaceutical Industry</title> <atom:link href="https://international-pharma.com/feed/" rel="self" type="application/rss+xml" /> <link>https://international-pharma.com</link> <description>Peer Reviewed, Contemporary, Authoritative</description> <lastBuildDate>Tue, 04 Nov 2025 14:34:14 +0000</lastBuildDate> <language>en-GB</language> <sy:updatePeriod> hourly </sy:updatePeriod> <sy:updateFrequency> 1 </sy:updateFrequency> <generator>https://wordpress.org/?v=6.8.3</generator> <image> <url>https://international-pharma.com/wp-content/uploads/2022/01/Favicon-IPI-150x150.png</url> <title>International Pharmaceutical Industry</title> <link>https://international-pharma.com</link> <width>32</width> <height>32</height></image> <item> <title>Fast, Precise, Efficient: The Freeze-drying Revolution</title> <link>https://international-pharma.com/fast-precise-efficient-the-freeze-drying-revolution/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Tue, 04 Nov 2025 14:34:13 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41780</guid> <description><![CDATA[Tempris wins ISPE RAYA Award 2025 in the “Drug Product” category Tempris, the innovation leader in wireless in-process product temperature control for freeze-drying, is delighted to announce that it has been presented with the 2025 ISPE Robotics Applications of the Year (RAYA) award in the “Drug Product” category for its closed-loop temperature control, which provides […]]]></description> <content:encoded><![CDATA[<p><strong>Tempris wins ISPE RAYA Award 2025 in the “Drug Product” category</strong></p> <p>Tempris, the innovation leader in wireless in-process product temperature control for freeze-drying, is delighted to announce that it has been presented with the 2025 ISPE Robotics Applications of the Year (RAYA) award in the “Drug Product” category for its closed-loop temperature control, which provides continuous product temperature monitoring and endpoint determination of primary drying to reduce freeze-drying losses, speed up production, and increase margins.</p> <p>The manufacture of sterile injectables is one of the most demanding processes in the pharmaceutical industry, and freeze-drying plays a key role in this process. Yet almost 100 percent of parenteral drugs are currently manufactured without continuous product temperature monitoring—a common cause of quality defects and batch losses. Tempris closed-loop control is revolutionising pharmaceutical freeze-drying by combining wireless real-time temperature measurement, robot-assisted aseptic sensor placement, and the intelligent LyoCLC<sup>®</sup> control software.</p> <p>“This award is a great honour for the entire team, and our partners as well,” says Anton Mangold, CEO of Tempris. “It demonstrates once again that improving production quality plays a central role in ensuring a reliable supply of medicines. Our project impressively demonstrates how robotics, PAT technology, and AI-supported process control are together paving the way to Pharma 4.0.”</p> <p>The award ceremony took place as part of this year’s ISPE D/A/CH conference “Robotics Workshop and RAYA Award 2025” on 26 September 2025 in Hillerød, Denmark. Tempris was nominated in the drug product category alongside Merck Serono, HOF Sonderanlagenbau, and Stäubli Robotics.</p> <p><strong>Precise monitoring, higher quality, lower costs</strong></p> <p>The jury was particularly impressed by the battery-free, real-time temperature monitoring, the automated workflows using robots, as well as the strict compliance with regulatory requirements and guaranteed traceability, which take the freeze drying of sterile injectables to a new level by removing the need for speculation and excessive safety margins, and instead providing the means for data-driven decisions and maximised efficiency. With Tempris’ closed-loop control, manufacturers achieve:</p> <p>– Up to 30% shorter drying times with reproducible product quality</p> <p>– Faster product launches – 40-50% reduction in time-to-market</p> <p>– Lower manufacturing cost of goods (COGs) and improved margins</p> <p>– Shortened return on investment (ROI) to below 1.3 years and, in the event of deviations, even positive returns within a few months.</p> <p></p> <p><strong>About Tempris technology</strong></p> <p>1. The wireless and battery-free Tempris sensors measure the product temperature in real time directly in the bottle / vial during the drying process. The Tempris sensors are briefly activated by a radio signal and oscillate at their own quartz frequency. The resulting signal is recorded in milliseconds, evaluated by the transmitter / receiver unit, and forwarded to the SCADA interface. The technology can be retrofitted to virtually all freeze dryers and is compliant with regulatory requirements worldwide.</p> <p>2. The robot places the sensors in just a few seconds – fully automated and completely sterile. Each sensor is identified, documented, and automatically placed at defined critical positions within the batch. During the freeze-drying process, the real-time data is then streamed directly to the system.</p> <p>3. At the software level, the digital twin makes the entire process visible, allowing immediate action to be taken in response to deviations. This creates a dynamic system that guarantees a consistent output — and thus reliable quality — even with variable input. With the help of AI and advanced algorithms, LyoCLC<sup>® </sup>also predicts the exact endpoint of the primary drying process. This level of precision surprised even experienced freeze-drying experts.</p> <p>For more information, visit <a href="http://www.tempris.com/de/" target="_blank" rel="noopener">www.tempris.com</a></p> <p></p>]]></content:encoded> </item> <item> <title>Ardena Strengthens Executive Leadership with Two Key Appointments</title> <link>https://international-pharma.com/ardena-strengthens-executive-leadership-with-two-key-appointments/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Tue, 04 Nov 2025 14:29:12 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41778</guid> <description><![CDATA[Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointment of Dipesh Patel as Chief Quality Officer and Peter Rose as Chief Information Officer. These appointments strengthen Ardena’s executive leadership team and reflect its continued focus on quality, compliance, and digital integration across its global network. Dipesh […]]]></description> <content:encoded><![CDATA[<p><a href="https://tracking.us.nylas.com/l/802b5d66a8ae4295b4dae856daac97dd/1/1bd7288db1c73c5864926b331463286fc609ba7db976776eda2b9db6e8ffe9d9?cache_buster=1762184069" target="_blank" rel="noreferrer noopener">Ardena</a>, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointment of Dipesh Patel as Chief Quality Officer and Peter Rose as Chief Information Officer. These appointments strengthen Ardena’s executive leadership team and reflect its continued focus on quality, compliance, and digital integration across its global network.<br></p> <p>Dipesh Patel brings more than 25 years of experience in the pharmaceutical industry, having held senior leadership roles across CDMOs, virtual biotech companies, and large-scale manufacturing organizations. With an academic background in Chemistry, Biology, and Toxicology, he has built a strong track record in both Quality and Operations, overseeing a broad range of dosage forms and regulatory frameworks. His global experience provides deep insight into diverse regulatory requirements and the practical implementation of robust quality systems across multiple regions. Most recently, Dipesh served as Senior Vice President, Quality, at Accord Healthcare, and prior to that held leadership roles at Catalent as Vice President Quality and Site General Manager. He is also a certified EU Qualified Person (QP). At Ardena, Dipesh will lead the company’s Quality and Regulatory organization, further strengthening global processes, ensuring ongoing compliance, and fostering a culture of operational excellence across the network.<br></p> <p>Peter Rose joins Ardena with over 25 years of Information Technology leadership experience across multiple industries. Most recently, he was the global head of IT infrastructure and security at Diversey, a global chemical manufacturer, driving technology-enabled transformation and leading a successful IT migration of the company into the Solenis Group. Before that, he spent a decade at Catalent, where he oversaw all global IT systems supporting quality, analytical, and manufacturing operations. Earlier in his career, Peter served in the Royal Air Force as an aircraft engineer, establishing a strong technical foundation that continues to shape his pragmatic, results-driven approach. At Ardena, he will build on the company’s robust digital infrastructure by further integrating enterprise-wide IT systems and advancing automation, AI, and cybersecurity to strengthen resilience, enhance productivity, and foster collaboration.<br></p> <p>“These appointments mark an important step in strengthening Ardena’s foundation as we accelerate our global growth journey and expand the capabilities that enable next-generation precision medicines.” said Jeremie Trochu, Ardena’s Chief Executive Officer. “Our continued investment in IT integration and digital infrastructure is transforming how we operate — advancing productivity, automation, and AI to support sustainable growth. At the same time, our strong regulatory track record and deep commitment to quality remain the backbone of our operations. With Dipesh and Peter joining our leadership team, we continue to build on our culture of operational excellence and integrated solutions for our customers, aligned with our mission to enable the development of next generation treatments get into the clinic and to patients faster”.<br></p> <p><strong>END</strong></p> <p><strong>About Ardena</strong></p> <p>Ardena is a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) dedicated to advancing precision medicines. Its integrated solutions enable innovative and complex molecules through services in nanomedicine, drug product and substance manufacturing, solid-state chemistry, bioanalytical services, and CMC regulatory support.<br></p> <p>More information at <a href="https://tracking.us.nylas.com/l/802b5d66a8ae4295b4dae856daac97dd/2/fe65b4d418db6a07e579eadbf45966fed19f650b993202846312f2aa8a83a155?cache_buster=1762184069" target="_blank" rel="noreferrer noopener">https://ardena.com/</a></p>]]></content:encoded> </item> <item> <title>API China Strengthens Its Role as Asia’s Pharma Powerhouse Heads to Chongqing for its 93rd edition</title> <link>https://international-pharma.com/api-china-strengthens-its-role-as-asias-pharma-powerhouse-heads-to-chongqing-for-its-93rd-edition/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Mon, 27 Oct 2025 15:10:16 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41767</guid> <description><![CDATA[ API China, Asia’s authoritative exhibition for pharmaceutical ingredients and manufacturing, will convene its 93rd edition at the Chongqing International Expo Center from 12–14 November 2025. Held twice annually, the event is one of the largest gatherings of the pharmaceutical supply chain, bringing together more than 1,200 exhibitors and close to 30,000 industry professionals, including over 5,000 pharmaceutical […]]]></description> <content:encoded><![CDATA[<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="682" src="https://international-pharma.com/wp-content/uploads/2025/10/1.-APIChinaChongqing-1024x682.jpg" alt="" class="wp-image-41768" srcset="https://international-pharma.com/wp-content/uploads/2025/10/1.-APIChinaChongqing-1024x682.jpg 1024w, https://international-pharma.com/wp-content/uploads/2025/10/1.-APIChinaChongqing-300x200.jpg 300w, https://international-pharma.com/wp-content/uploads/2025/10/1.-APIChinaChongqing-768x512.jpg 768w, https://international-pharma.com/wp-content/uploads/2025/10/1.-APIChinaChongqing-1536x1023.jpg 1536w, https://international-pharma.com/wp-content/uploads/2025/10/1.-APIChinaChongqing-2048x1364.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure> <p> <strong><a href="https://www.apichina.com.cn/en" target="_blank" rel="noreferrer noopener">API China</a></strong>, Asia’s authoritative exhibition for pharmaceutical ingredients and manufacturing, will convene its 93<sup>rd</sup> edition at the Chongqing International Expo Center from 12–14 November 2025. Held twice annually, the event is one of the largest gatherings of the pharmaceutical supply chain, bringing together more than 1,200 exhibitors and close to 30,000 industry professionals, including over 5,000 pharmaceutical manufacturers, across 70,000 square metres of exhibition space.</p> <p>With a heritage spanning more than four decades, API China stands as the most established platform of its kind. Generations of industry professionals have trusted it as the meeting point to gain insight, discover innovation, and forge lasting business connections in China’s fast-evolving pharmaceutical and biopharmaceutical landscape.</p> <p><strong>Four Pillars, One Integrated Ecosystem</strong></p> <p>The exhibition’s strength lies in its breadth. Beyond active pharmaceutical ingredients, the event encompasses the full scope of pharmaceutical manufacturing. Four interlinked pillars form the backbone of the show: <strong>API China</strong>, which highlights cutting-edge APIs, biologics, and contract manufacturing expertise; <strong>PHARMEX</strong>, dedicated to the excipients that shape drug formulation; <strong>PHARMPACK</strong>, showcasing intelligent and sustainable pharmaceutical packaging; and <strong>SINOPHEX</strong>, focused on advanced machinery, cleanroom, and laboratory technologies. Together, they reflect the complete journey from molecule to medicine, offering visitors a holistic view of the ecosystem.</p> <figure class="wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex"><figure class="wp-block-image size-large"><img decoding="async" width="1024" height="682" data-id="41769" src="https://international-pharma.com/wp-content/uploads/2025/10/2.-APIChina-Showfloor1-1024x682.jpg" alt="" class="wp-image-41769" srcset="https://international-pharma.com/wp-content/uploads/2025/10/2.-APIChina-Showfloor1-1024x682.jpg 1024w, https://international-pharma.com/wp-content/uploads/2025/10/2.-APIChina-Showfloor1-300x200.jpg 300w, https://international-pharma.com/wp-content/uploads/2025/10/2.-APIChina-Showfloor1-768x511.jpg 768w, https://international-pharma.com/wp-content/uploads/2025/10/2.-APIChina-Showfloor1-1536x1022.jpg 1536w, https://international-pharma.com/wp-content/uploads/2025/10/2.-APIChina-Showfloor1-2048x1363.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure> <figure class="wp-block-image size-large"><img decoding="async" width="1024" height="682" data-id="41770" src="https://international-pharma.com/wp-content/uploads/2025/10/3.-APIChina-Showfloor2-1024x682.jpg" alt="" class="wp-image-41770" srcset="https://international-pharma.com/wp-content/uploads/2025/10/3.-APIChina-Showfloor2-1024x682.jpg 1024w, https://international-pharma.com/wp-content/uploads/2025/10/3.-APIChina-Showfloor2-300x200.jpg 300w, https://international-pharma.com/wp-content/uploads/2025/10/3.-APIChina-Showfloor2-768x512.jpg 768w, https://international-pharma.com/wp-content/uploads/2025/10/3.-APIChina-Showfloor2-1536x1024.jpg 1536w, https://international-pharma.com/wp-content/uploads/2025/10/3.-APIChina-Showfloor2-2048x1365.jpg 2048w, https://international-pharma.com/wp-content/uploads/2025/10/3.-APIChina-Showfloor2-scaled-264x176.jpg 264w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></figure> <p>To ensure meaningful engagement at this scale, API China will run dedicated business matching activities designed to connect buyers and suppliers with shared priorities. By facilitating purposeful introductions, the programme turns the sheer diversity of exhibitors into tangible opportunities for collaboration and growth.</p> <p>A full list of exhibitors can be accessed here: <a href="https://www.apichina.com.cn/#/companyList" target="_blank" rel="noreferrer noopener">www.apichina.com.cn/#/companyList</a></p> <p><strong>Insights and Expertise Beyond the Exhibition Floor</strong></p> <figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="684" src="https://international-pharma.com/wp-content/uploads/2025/10/4.-APIChina-Conference2-1024x684.jpg" alt="" class="wp-image-41771" srcset="https://international-pharma.com/wp-content/uploads/2025/10/4.-APIChina-Conference2-1024x684.jpg 1024w, https://international-pharma.com/wp-content/uploads/2025/10/4.-APIChina-Conference2-300x200.jpg 300w, https://international-pharma.com/wp-content/uploads/2025/10/4.-APIChina-Conference2-768x513.jpg 768w, https://international-pharma.com/wp-content/uploads/2025/10/4.-APIChina-Conference2-1536x1026.jpg 1536w, https://international-pharma.com/wp-content/uploads/2025/10/4.-APIChina-Conference2-2048x1368.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure> <p>Alongside the exhibition floor, API China features a robust programme of forums and conferences. Of special note is the <strong>IPEC Federation China Excipient Conference</strong>, co-organized by IPEC China and Reed Sinopharm Exhibitions. Launched in 2012, the conference is the foremost platform for excipient-focused dialogue, convening regulators, experts, and manufacturers to exchange perspectives on GMP, regulatory reforms, technological advances, and the evolving role of excipients in drug development.</p> <p>Reinforcing API China’s role as a hub for industry knowledge, the <strong>40<sup>th</sup></strong><strong> China Pharmaceutical Industry Market Information Conference</strong> will gather policy leaders, data experts, and enterprise representatives to examine the current landscape and outlook of China’s pharmaceutical sector. With discussions on innovation, market dynamics, and global competitiveness, the conference offers an authoritative pulse of the industry — affirming API China’s position as a catalyst for insight, collaboration, and progress.</p> <p><strong>Secure Your Spot at Asia’s Premier Pharmaceutical Marketplace</strong></p> <p>“API China is where ideas, innovations, and partnerships take root and grow,” said a spokesperson for Reed Sinopharm Exhibitions. “As the industry evolves, our commitment is to continue presenting the most trusted platform for global audiences to benefit from meaningful exchange and collaboration.”</p> <p>Industry professionals are invited to pre-register for API China 2025 (Chongqing) at: <a href="https://reg.reed-sinopharm.com/pc/#/login?id=d53d1235522243d7b93a68f807e291cb&channelUuid=a04d67b16100422bb1e9db3e81555964" target="_blank" rel="noreferrer noopener">https://bit.ly/93APIChinaprereg</a>.</p> <p><em>###</em></p> <figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="1000" height="500" src="https://international-pharma.com/wp-content/uploads/2025/10/API-China_GroupLogo.png" alt="" class="wp-image-41772" srcset="https://international-pharma.com/wp-content/uploads/2025/10/API-China_GroupLogo.png 1000w, https://international-pharma.com/wp-content/uploads/2025/10/API-China_GroupLogo-300x150.png 300w, https://international-pharma.com/wp-content/uploads/2025/10/API-China_GroupLogo-768x384.png 768w" sizes="(max-width: 1000px) 100vw, 1000px" /></figure> <p><strong>About API China</strong></p> <p>API China is the country’s leading exhibition for the pharmaceutical and biopharmaceutical industries, serving as a trusted platform for sourcing, innovation, and partnership. It brings together the full spectrum of the pharma, health, and nutrition ecosystem—from active pharmaceutical ingredients (APIs), intermediates, and excipients to formulations, packaging, manufacturing equipment, CDMO services, and biotech solutions. Organised by Reed Sinopharm Exhibitions, API China connects global professionals with China’s dynamic life sciences market through high-level exhibitions, forums, and strategic exchange.</p> <p>More information: <a href="https://www.apichina.com.cn/en" target="_blank" rel="noreferrer noopener">www.apichina.com.cn/en</a></p> <p><strong>Follow us on social media:</strong></p> <figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>LinkedIn</td><td><a href="https://www.linkedin.com/company/apichina/" target="_blank" rel="noreferrer noopener">https://www.linkedin.com/company/apichina/</a></td></tr></tbody></table></figure> <p></p> <p></p> <p></p>]]></content:encoded> </item> <item> <title>IMCD Showcases Greener, Smarter, Patient-Centric Solutions at CPHI Frankfurt 2025</title> <link>https://international-pharma.com/imcd-showcases-greener-smarter-patient-centric-solutions-at-cphi-frankfurt-2025/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Fri, 24 Oct 2025 10:05:58 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41763</guid> <description><![CDATA[Rotterdam, the Netherlands (24 October 2025) – IMCD Group (“IMCD” or “Company”), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, will exhibit at CPHI Frankfurt 2025 from 28 to 30 October, where its experts will unveil a portfolio of greener, smarter, patient-centric solutions designed to meet the evolving demands of the pharmaceutical industry. At this year’s […]]]></description> <content:encoded><![CDATA[<p><strong>Rotterdam</strong><strong>, the Netherlands (24 October 2025) –</strong> IMCD Group (“IMCD” or “Company”), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, will exhibit at CPHI Frankfurt 2025 from 28 to 30 October, where its experts will unveil a portfolio of greener, smarter, patient-centric solutions designed to meet the evolving demands of the pharmaceutical industry.</p> <p>At this year’s event, IMCD will highlight how its technical expertise, sustainable innovation, and collaborative approach are helping customers accelerate development and deliver better outcomes for patients.</p> <p>Showcasing a curated selection of formulations, these concepts deliver tangible solutions to the pressing challenges in pharmaceutical development today. Concepts at the booth will sit under three key themes:</p> <ul class="wp-block-list"><li><strong>Greener</strong>: Solutions that deliver sustainability across the pharmaceutical value chain. From sourcing eco-friendly excipients to promoting energy-efficient manufacturing processes. These concepts reduce environmental impact without compromising performance.</li></ul> <ul class="wp-block-list"><li><strong>Smarter</strong>: Leveraging its global network of technical centres and formulation experts, IMCD delivers intelligent solutions that solve complex challenges – including solubility enhancement, modified release, and taste masking. Attendees will discover innovative prototypes such as dual-layer tablets, high-load capsules, and advanced coating systems.</li></ul> <ul class="wp-block-list"><li><strong>Patient-centric</strong>: Formulation concepts designed with the end-user in mind. Whether it’s improving compliance through palatable paediatric formats or enhancing bioavailability for chronic therapies, IMCD will showcase patient-focused solutions that are safer, more effective, and easier to take.</li></ul> <p>At the booth, IMCD experts will present <strong>six innovative concepts</strong>, each demonstrating the company’s ability to combine regulatory insight with formulation excellence to support the rapid development of high-value therapies:</p> <ul class="wp-block-list"><li><strong>Apixaban coated tablet</strong> – A more sustainable alternative to traditional roller compaction. The direct compression formulation reduces manufacturing steps, energy use, and cleaning, while maintaining comparable performance to the originator.</li></ul> <ul class="wp-block-list"><li><strong>Apremilast ointment</strong> – A novel, more patient-friendly topical treatment concept for psoriasis that enhances API solubility and skin permeation, offering a non-greasy, easy-to-apply formulation free from the side effects of oral therapy.</li></ul> <ul class="wp-block-list"><li><strong>Caffeine SR effervescent tablet</strong> – A dual-release concept combining immediate and sustained caffeine delivery for long-lasting energy without the “crash,” with taste masking and effervescent convenience that promote hydration and compliance.</li></ul> <ul class="wp-block-list"><li><strong>Ginkgo coated tablet</strong> – A direct compression, once-a-day liposomal ginkgo biloba tablet that improves absorption, ensures stability, and delivers performance in a small, easy-to-swallow format.</li></ul> <ul class="wp-block-list"><li><strong>Terbinafine film forming solution</strong> – A transparent, water-resistant film that provides prolonged antifungal action with a pleasant, non-tacky feel, for an advanced, patient-friendly approach to treating athlete’s foot.</li></ul> <ul class="wp-block-list"><li><strong>Mucoadhesive gel platform</strong> – A versatile platform for targeted, patient-centric drug delivery across oral, buccal, vaginal, and other mucosal routes, extending retention time and offering new opportunities for differentiation and patient comfort.</li></ul> <p>More information are available on our dedicated page <a href="https://link.mediaoutreach.meltwater.com/ls/click?upn=u001.dGXcScUs4v-2FMAecsBUXk4cN4Y-2BUpe-2FDv8Tofj-2B2USWjiUR-2BAE-2Br9XxQ6811yLiVNleVzx40BOvkkJYMGEvM0LH-2BmiukPD3hueKYcSGwUvzuVyLk7tFPkxb0mKPDhUKpHsCE2bCxVTulTWGhNvKCGim-2BK5ELrSzbGZ9NNZdtIS-2BJxBKyMJhg-2BnehN4wY29r0RhNISALiw7NokGroVvJY4KKlOPyEXnvJPl-2F9TcVvFOlNKZK4mIntP2Rs03tlFJmR20yZ1hVpDj3GV6EjTBlQ89Q-3D-3D3c1K_ENosFV7hroK-2BHw29waVBdDpfVwtzsAxZQkfj-2FZfXK65ncRF0LYWe-2BSSFCMf8N8xCkTNeXQpWdcpRBo91PlcoVThdVx7r1CvCP7CSJL1RhrdtE3oEwID7i-2F-2BgvFfWbsxcs6T3MBPRvCVQhZy1TsGVm8GEtxcPk92Gf7tSAhn8yK9I31S8qgJ69FnQ0NA1GWLM1u-2F1DGlGQYuRiVS6e3d0Lyvq71VWZaBkWNubAVki5IXWDnSZqZSIY4BGIxh3KaRW3Hcvs8n-2B-2Flhh-2B-2B8pzYfk6ST9wGK6DTDw3F-2BuLviGR2SczH6CMI0Kk3JHLa1F2PgshhkMLEFn8Tx4pypdkg74GJGOVCHjIs1NCsDjj3lLjs3DZZtJ5Qlbpp1ISafnXXP1" target="_blank" rel="noreferrer noopener"><strong>here</strong></a>.</p> <p><strong>Chhanda Kapadia</strong>, Group Director, Technical Services, IMCD<strong> </strong>Pharmaceuticals, comments: <em>“Our presence at CPHI reflects our commitment to co-creating solutions that are not only innovative but also more sustainable and patient focused. They are a first-class example of our globally connected network of technical laboratories. We are looking forward to showcasing these innovations and engaging with partners and customers to explore how we can shape the future of healthcare together”.</em></p> <p>IMCD invites visitors to <strong>Booth 8.0S36 </strong>to meet its technical experts and explore how its tailored solutions can help bring better medicines to market.</p> <figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://international-pharma.com/wp-content/uploads/2025/10/IMCD-Laboratory-in-Cologne-Germany-lr-1024x683.jpg" alt="" class="wp-image-41765" srcset="https://international-pharma.com/wp-content/uploads/2025/10/IMCD-Laboratory-in-Cologne-Germany-lr-1024x683.jpg 1024w, https://international-pharma.com/wp-content/uploads/2025/10/IMCD-Laboratory-in-Cologne-Germany-lr-300x200.jpg 300w, https://international-pharma.com/wp-content/uploads/2025/10/IMCD-Laboratory-in-Cologne-Germany-lr-768x512.jpg 768w, https://international-pharma.com/wp-content/uploads/2025/10/IMCD-Laboratory-in-Cologne-Germany-lr-1536x1024.jpg 1536w, https://international-pharma.com/wp-content/uploads/2025/10/IMCD-Laboratory-in-Cologne-Germany-lr-2048x1365.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure> <p><sub><sup>IMCD Laboratory in Cologne, Germany (photo: IMCD)</sup></sub></p> <p></p> <figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="725" src="https://international-pharma.com/wp-content/uploads/2025/10/IMCD-booth-at-CPHI-Milan-2024-lr-1024x725.jpg" alt="" class="wp-image-41764" srcset="https://international-pharma.com/wp-content/uploads/2025/10/IMCD-booth-at-CPHI-Milan-2024-lr-1024x725.jpg 1024w, https://international-pharma.com/wp-content/uploads/2025/10/IMCD-booth-at-CPHI-Milan-2024-lr-300x212.jpg 300w, https://international-pharma.com/wp-content/uploads/2025/10/IMCD-booth-at-CPHI-Milan-2024-lr-768x544.jpg 768w, https://international-pharma.com/wp-content/uploads/2025/10/IMCD-booth-at-CPHI-Milan-2024-lr-1536x1088.jpg 1536w, https://international-pharma.com/wp-content/uploads/2025/10/IMCD-booth-at-CPHI-Milan-2024-lr-2048x1450.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure> <p><sup>IMCD booth at CPHI Milan 2024 (photo: IMCD)</sup></p> <p></p> <p><strong>About IMCD Group </strong> </p> <p>IMCD Group, headquartered in Rotterdam, The Netherlands, is a leading global partner for the distribution and formulation of speciality chemicals and ingredients. A strong, innovative business partner and solutions provider for producers of consumer, industrial and durable goods in multiple business sectors: Advanced Materials, Beauty & Personal Care, Coatings & Construction, Food & Nutrition, Home Care and Industrial & Institutional Care (I&I), Industrial Solutions, Lubricants & Energy, and Pharmaceuticals.</p> <p>In partnership with our suppliers, we offer a broad and deep product portfolio. With our over 80 application laboratories across 60 countries, we co-create formulations and offer ’Sustainable Solutions’ that allow our business partners to make products with a positive impact on the world of today, and tomorrow. Our teams focus on providing commercial and operational excellence, using the best digital and logistics tools available to create a world of opportunity for our partners. </p> <p>In 2024, with over 5,100 employees, IMCD realised revenues of EUR 4,728 million. IMCD N.V.’s shares are traded at Euronext Amsterdam (symbol: IMCD) and are included in the Dutch ESG AEX index, as one of 25 companies within the AEX and AMX indices demonstrating best ESG practices.</p> <p>For further information, please visit <a href="https://link.mediaoutreach.meltwater.com/ls/click?upn=u001.B9XWmt9BoFMJ3oF7EIovPvsXQ4O1WXDpJ5L-2FKzWs3rnVJH9mS4g8q1PwLEALWBh0usll_ENosFV7hroK-2BHw29waVBdDpfVwtzsAxZQkfj-2FZfXK65ncRF0LYWe-2BSSFCMf8N8xCkTNeXQpWdcpRBo91PlcoVThdVx7r1CvCP7CSJL1RhrdtE3oEwID7i-2F-2BgvFfWbsxcs6T3MBPRvCVQhZy1TsGVm8GEtxcPk92Gf7tSAhn8yK9I31S8qgJ69FnQ0NA1GWLM1u-2F1DGlGQYuRiVS6e3d0Lyvq71VWZaBkWNubAVki5IU93-2BVq57dO4SZblnHttl-2FZIp7h6goUA2q5C8GuPMsabgNU-2FZ-2BU-2BnkZiWL-2FE-2BlnmJhiLNZ2ua2Pnd-2BgIO-2Bny87dj6EYA1ZawtcqgUpNR-2FyR0IkbwhFFJVSw2Jfga8EA3oMikbYjM1B8AFksKmPFpzZ4" target="_blank" rel="noreferrer noopener">www.imcdgroup.com</a> </p> <p><strong>Media contact</strong></p> <p>IMCD Media Centre</p> <p><a href="mailto:mediarelations@imcdgroup.com">mediarelations@imcdgroup.com</a></p> <p>IMCD Group</p> <p>Muriel Werlé</p> <p>Group Communications Director</p> <p><a href="mailto:muriel.werle@imcdgroup.com">muriel.werle@imcdgroup.com</a></p> <p>IMCD Pharmaceuticals</p> <p>Eleanor Dampier</p> <p>Global Communications & Marketing Director, Pharmaceuticals & UK</p> <p><a href="mailto:eleanor.dampier@imcd.co.uk">eleanor.dampier@imcd.co.uk</a></p> <p>IMCD Germany</p> <p>Caren Hassmann</p> <p>Head of Marketing & Communications, Germany</p> <p><a href="mailto:caren.hassmann@imcd.de">caren.hassmann@imcd.de</a></p>]]></content:encoded> </item> <item> <title>Emerson’s New Pressure Transmitter Delivers Increased Performance, Flexibility and Operational Insights</title> <link>https://international-pharma.com/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-and-operational-insights/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Thu, 23 Oct 2025 14:19:26 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41757</guid> <description><![CDATA[Rosemount 4051S provides 20-year warranty and stability, comprehensive diagnostics and enhanced ease-of-use SHAKOPEE, Minn. (Oct. 23, 2025) – Today Emerson announced the release of the Rosemount™ 4051S Pressure Transmitter, a new industrial measurement solution with the flexibility to meet the most demanding pressure measurement challenges by increasing performance and operational insights. This innovative pressure transmitter can […]]]></description> <content:encoded><![CDATA[<p><em>Rosemount 4051S provides 20-year warranty and stability, comprehensive diagnostics and enhanced ease-of-use</em></p> <p>SHAKOPEE, Minn. (Oct. 23, 2025) – Today Emerson announced the release of the <a href="https://www.emerson.com/en-us/automation/measurement-instrumentation/pressure-measurement/pressure-measurement-innovations" target="_blank" rel="noreferrer noopener">Rosemount<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> 4051S Pressure Transmitter</a>, a new industrial measurement solution with the flexibility to meet the most demanding pressure measurement challenges by increasing performance and operational insights.</p> <p>This innovative pressure transmitter can provide local real-time control, eliminating the need for a separate device, such as a programmable logic controller. This functionality is provided by two relay switches, each of which can be configured to provide on/off control of pumps, motors and other equipment. These switches can also provide alerts based on pressure, flow, totalised flow, level, volume or module temperature.</p> <figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="785" src="https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024418-1024x785.png" alt="" class="wp-image-41758" srcset="https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024418-1024x785.png 1024w, https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024418-300x230.png 300w, https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024418-768x589.png 768w, https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024418-1536x1178.png 1536w, https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024418-2048x1570.png 2048w, https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024418-scaled-211x162.png 211w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure> <p><sup>The Rosemount 4051S Pressure Transmitter provides 20-year warranty and stability, comprehensive diagnostics and enhanced ease-of-use.</sup></p> <p></p> <p>“The Rosemount 4051S Pressure Transmitter is designed to provide exceptional versatility and performance, helping customers improve operations and expand their pressure measurement capabilities across a broad range of industrial applications,” said Nathan Stokes, vice president pressure products with Emerson’s measurement instrumentation business.</p> <p>The Rosemount 4051S has been engineered to withstand the toughest processes and the harshest environments, with a 20-year warranty and 20-year stability specification, both unique to the pressure transmitter market. A fast response time of 40 milliseconds allows the 4051S to be used in the most demanding applications. A best-in-class 800:1 turndown ratio reduces the number of unique models needed to be kept in stock, streamlining inventory.</p> <p>Advanced diagnostics provide more insights, with loop integrity continuously monitoring the health of the entire electrical loop to detect potential failures. Plugged impulse line detection alerts plant personnel so they can take action, and the transmitter can also diagnose other abnormal conditions, such as cavitation, using its built-in process intelligence. Built-in calibration and diagnostic logs provide the information needed to optimise maintenance and perform root cause analysis.</p> <figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="540" src="https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024420-1024x540.jpg" alt="" class="wp-image-41759" srcset="https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024420-1024x540.jpg 1024w, https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024420-300x158.jpg 300w, https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024420-768x405.jpg 768w, https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024420-1536x810.jpg 1536w, https://international-pharma.com/wp-content/uploads/2025/10/emersons-new-pressure-transmitter-delivers-increased-performance-flexibility-operational-insights-en-us-12024420-2048x1080.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure> <p><sub>Emerson’s Rosemount 4051S Pressure Transmitter provides real-time control in some applications, eliminating the need for a separate device, such as a programmable logic controller.</sub></p> <p></p> <p>The graphical, backlit display is larger than previous models, making it easier to read and allowing inclusion of more descriptive warning messages, an always-on process variable value, and a customisable secondary area. The display can be configured in seven languages, and the intuitive user interface speeds and simplifies operator interactions, while reducing the risk of errors.</p> <p>Bluetooth® connectivity from up to 15 metres (50 feet) away improves safety by allowing plant personnel to access the transmitter so they can avoid entering hazardous areas. This fast and easy connectivity increases productivity, reliability and safety by simplifying operator rounds. Configuration and troubleshooting are improved because operators are informed as to which devices need attention, and the AMS Device Configurator mobile app provides a seamless experience across all devices.</p> <p>Guided proof-testing and logging simplifies these tasks with a step-by-step process. Built-in proof-testing provides reliable verification of instrument functionality to improve operational efficiency and safety, and the transmitter is certified to Safety Integrity Level 2/3 and IEC (International Electrotechnical Commission) 61508. Partial proof-testing includes in-situ capability, allowing you to extend proof-test intervals without applying an external pressure source.</p> <p>Learn more at <a href="http://www.emerson.com/Rosemount4051S" target="_blank" rel="noreferrer noopener">www.Emerson.com/Rosemount4051S</a>.</p> <p><a href="https://players.brightcove.net/2270581185001/default_default/index.html?videoId=6373057703112#xd_co_f=NDg5Mjk0MGItOGIwMi00YTdhLThjMDgtM2MxYzQxMGU4NDhh~" target="_blank" rel="noreferrer noopener">players.brightcove.net/2270581185001/default_default/index.html?videoId=6373057703112#xd_co_f=NDg5Mjk0MGItOGIwMi00YTdhLThjMDgtM2MxYzQxMGU4NDhh~</a></p> <p><sub>The Rosemount 4051S Pressure Transmitter is engineered to give customers more insights, more performance and more flexibility.</sub></p> <p></p> <p><strong>Additional resources</strong></p> <p>Join the <a href="https://emersonexchange365.com/" target="_blank" rel="noreferrer noopener">Emerson Exchange 365 Community</a></p> <p>Connect with Emerson via <a href="https://x.com/emr_automation" target="_blank" rel="noreferrer noopener">X</a><a href="https://www.facebook.com/EmersonAutomationSolutions/" target="_blank" rel="noreferrer noopener">Facebook</a><a href="https://www.linkedin.com/showcase/emerson-automation-solutions/posts/?feedView=all" target="_blank" rel="noreferrer noopener">LinkedIn</a><a href="https://www.youtube.com/Emersonautomationsolutions" target="_blank" rel="noreferrer noopener">YouTube</a></p> <p><strong>About Emerson</strong></p> <p>Emerson (NYSE: EMR) is a global industrial technology leader that provides advanced automation. With an unmatched portfolio of intelligent devices, control systems and industrial software, Emerson delivers solutions that automate and optimise business performance. Headquartered in St. Louis, Missouri, Emerson combines innovative technology with proven operational excellence to power the future of automation. For more information, visit <a href="https://www.emerson.com/en-us" target="_blank" rel="noreferrer noopener">Emerson.com</a>.</p> <p><strong>Further press information</strong></p> <p>HHC Lewis, Southampton, UK</p> <p><a href="mailto:ian.kelly@hhc-lewis.co.uk">ian.kelly@hhc-lewis.co.uk</a></p> <p>Ref: 504635</p>]]></content:encoded> </item> <item> <title>Agarose Bead Technologies Announces Global Expansion Plans and New Capabilities to Meet Rising Global Demand for Novel Therapies</title> <link>https://international-pharma.com/agarose-bead-technologies-announces-global-expansion-plans-and-new-capabilities-to-meet-rising-global-demand-for-novel-therapies/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Wed, 22 Oct 2025 09:48:01 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41750</guid> <description><![CDATA[The Spanish firm celebrates 25 years of delivering high-performance agarose resins for the worldwide bioprocessing industry Madrid, Spain, 20th Oct 25 – Agarose Bead Technologies (ABT), a leading manufacturer of high-quality agarose resins has today announced plans for further expansion, reinforcing its position as a strategic partner for biopharmaceutical companies developing next-generation therapies. For 25 years, ABT has worked […]]]></description> <content:encoded><![CDATA[<p><em>The Spanish firm celebrates 25 years of delivering high-performance agarose resins for the worldwide bioprocessing industry</em></p> <p>Madrid, Spain, 20th Oct 25 – <a href="https://tracking.us.nylas.com/l/3166d759bdf9457f8e627c4020cd26cc/0/fb484cd44990a2e88547272ac4bfe7ffabce92deda6b4bdcb5670f900adad346?cache_buster=1760951138" target="_blank" rel="noreferrer noopener">Agarose Bead Technologies</a> (ABT), a leading manufacturer of high-quality agarose resins has today announced plans for further expansion, reinforcing its position as a<strong> </strong>strategic partner for biopharmaceutical companies developing next-generation therapies.</p> <p>For 25 years, ABT has worked alongside biotech and pharma companies to provide scalable and reproducible chromatography solutions that are critical to the development and manufacturing of innovative therapies. ABT’s agarose resins are widely applied in the purification of monoclonal antibodies (mAbs), advanced cell and gene therapies (ATMPs), lipid nanoparticles (LNPs) for mRNA delivery, recombinant proteins, and therapeutic oligonucleotides.</p> <p>Following the $5 million investment in the expansion of its Burgos facility last year, ABT now has its sights set on expanding its global presence in new international markets, including India and the USA. It also plans to extend its expertise in tailor-made solutions by offering a design and manufacture of customised resins service for other biopharmaceutical companies. </p> <p>ABT will also invest in the scalability of its technologies and processes to support customers’ growth needs, and enhance its logistics and storage infrastructure to secure an uninterrupted global supply of products. Sustainability is a core focus for the business with plans to incorporate more efficient resource use, reduce waste, and apply greener production practices across its European facilities.</p> <p>The firm’s ambitious growth strategy comes as the team looks to continue to meet global demand for resins to support the purification of biologics, including monoclonal antibodies (mAbs), vaccines, recombinant proteins, therapeutic oligonucleotides, and advanced therapies. </p> <p>Carolina Egea, General Manager, Agarose Bead Technologies said: “As we celebrate our 25th anniversary, it’s incredible to reflect on how far we’ve come as a business. We are the only resin manufacturer in Spain, and we have played a significant role in the evolution of agarose resins.”</p> <p>Today, in addition to performing at the research level, agarose resins deliver on scalability, reproducibility, regulatory compliance, and cost-effectiveness for large-scale GMP manufacturing. They are a critical component in global health, helping to bring innovative therapies to patients around the world.</p> <p>Egea continues: “Reaching our 25th anniversary is both a proud moment and a springboard for the future. Looking ahead, we plan to invest approximately $10 million over the next five years to expand our capabilities and strengthen our role as a partner of choice for companies developing biologics and advanced therapies.</p> <p>“Today’s innovators don’t just need products — they need a trusted partner who can provide unique, flexible, and scalable solutions for the purification of molecules, whatever their nature. At ABT, we see our role as enabling these therapies to move from idea to impact, helping ensure patients around the world gain access to life-changing treatments.”</p> <p>ENDS</p> <p><strong>About Agarose Bead Technologies</strong></p> <p>Agarose Bead Technologies (ABT) is a premier manufacturer of high-quality agarose resins with locations in the US and Europe. The agarose resins, manufactured under a rigorous quality management system (QMS), are used in chromatographic purification, separation, or immobilization processes of biomolecules including proteins, antibodies, enzymes, and oligonucleotides in discovery, development, and cGMP production of biopharmaceuticals. Our custom products are made in compliance with client specifications in large scale – a unique capability in the industry. ABT is an ISO 9001:2015 certified company with cGMP facilities operated by experts with in-depth knowledge of agarose. Our expanding and growing global capabilities enable us to offer novel chromatography resins to meet the evolving needs of the biopharmaceutical Industry.</p>]]></content:encoded> </item> <item> <title>OpenEvidence and Veeva Announce Open Vista Partnership</title> <link>https://international-pharma.com/openevidence-and-veeva-announce-open-vista-partnership/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Wed, 22 Oct 2025 09:44:26 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41747</guid> <description><![CDATA[Veeva Systems (NYSE: VEEV) and OpenEvidence today announced the formation of a long-term partnership to jointly create and market Open Vista. Open Vista will use AI to increase patient access to clinical trials, accelerate drug discovery through better understanding of unmet needs, and improve understanding and adoption of existing approved medicines to provide better patient outcomes. “OpenEvidence has […]]]></description> <content:encoded><![CDATA[<p><a href="https://www.veeva.com/" target="_blank" rel="noreferrer noopener">Veeva Systems</a> (NYSE: VEEV) and <a href="https://www.openevidence.com/" target="_blank" rel="noreferrer noopener">OpenEvidence</a> today announced the formation of a long-term partnership to jointly create and market Open Vista. Open Vista will use AI to increase patient access to clinical trials, accelerate drug discovery through better understanding of unmet needs, and improve understanding and adoption of existing approved medicines to provide better patient outcomes.</p> <p>“OpenEvidence has become an accelerator for the dissemination of medical knowledge, with more than 40% of U.S. physicians actively using its point-of-care clinical decision support AI. By bridging the gap between peer-reviewed evidence and on-the-ground medical practice, OpenEvidence is streamlining and quickening the translation of medical research from bench to bedside,” said Daniel Nadler, CEO of OpenEvidence. “For many patients with serious illnesses who have exhausted first and second line therapies, clinical trials are their most promising form of healthcare. In partnering with Veeva, we now have a unique opportunity to go a step further and leverage the power of AI to connect physicians and patients to relevant clinical trials and cutting-edge therapies.”</p> <p>“We are very excited about our long-term partnership with OpenEvidence as we enter the AI chapter in life sciences,” said Veeva CEO Peter Gassner. “Combining the strengths of Veeva and OpenEvidence, we can use AI to bridge life sciences companies making life-saving medicines, patients, and the physicians who treat them. With Open Vista our aim is to help life sciences companies accelerate the development of effective new treatments, enable more patients to participate in clinical trials, and advance the understanding and adoption of existing medicines for better patient outcomes.”</p> <p>The first Open Vista product offerings are expected to be released in 2026.</p> <p><strong>About Veeva Systems<a></a></strong></p> <p>Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a <a href="https://www.veeva.com/pbc/" target="_blank" rel="noreferrer noopener">Public Benefit Corporation</a>, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit <a href="http://veeva.com/" target="_blank" rel="noreferrer noopener">veeva.com</a>.</p> <p><strong>About OpenEvidence</strong></p> <p><a href="https://www.openevidence.com/" target="_blank" rel="noreferrer noopener">OpenEvidence</a> is the fastest-growing clinical decision support platform in the United States, and the most widely used medical search engine among U.S. clinicians. OpenEvidence is trusted by hundreds of thousands of verified healthcare professionals to make high-stakes clinical decisions at the point of care that are sourced, cited, and grounded in peer-reviewed medical literature. Founded with the mission to organize and expand global medical knowledge, Open Evidence is actively used by more than 10,000 hospitals and medical centers and by over 40% of physicians in the United States.</p> <p><strong>Veeva Forward-Looking Statements</strong></p> <p>This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2025, which you can find <em><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1393052/000139305225000067/veev-20250731.htm#i7e129a0ad48d459ea13c21cd7e2de073_124" target="_blank" rel="noreferrer noopener">here</a></em> (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at <em><a href="https://www.sec.gov/" target="_blank" rel="noreferrer noopener">sec.gov</a></em>.</p> <p></p>]]></content:encoded> </item> <item> <title>Quotient Sciences and Biorasi Partner to Accelerate Early Phase Clinical Trials to Patient Proof-of-concept</title> <link>https://international-pharma.com/quotient-sciences-and-biorasi-partner-to-accelerate-early-phase-clinical-trials-to-patient-proof-of-concept/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Wed, 22 Oct 2025 09:43:05 +0000</pubDate> <category><![CDATA[News]]></category> <category><![CDATA[Uncategorised]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41745</guid> <description><![CDATA[Quotient Sciences, a leading global drug development, research and manufacturing accelerator, and Biorasi, a global clinical research organisation (CRO), today announced a strategic partnership to deliver fully integrated early phase clinical trial solutions. The partnership will combine Quotient Sciences’ expertise in early clinical development with Biorasi’s global patient recruitment capabilities to provide biotech and pharma Sponsors with a […]]]></description> <content:encoded><![CDATA[<p></p> <p><a href="https://tracking.us.nylas.com/l/5bc851cad33d4995b681c562ae0b83ac/0/a52b3f12cf9a13b67f5a0777a311e3288b94b1cef5b4f7600a10995ec114003e?cache_buster=1761042731" target="_blank" rel="noreferrer noopener">Quotient Sciences</a>, a leading global drug development, research and manufacturing accelerator, and <a href="https://tracking.us.nylas.com/l/5bc851cad33d4995b681c562ae0b83ac/1/2b72d247eb2fdab89c8b85781b2b2b27cd455d49e08f6b7a8bf730d3478927bf?cache_buster=1761042731" target="_blank" rel="noreferrer noopener">Biorasi</a>, a global clinical research organisation (CRO), today announced a strategic partnership to deliver fully integrated early phase clinical trial solutions. </p> <p>The partnership will combine Quotient Sciences’ expertise in <a href="https://tracking.us.nylas.com/l/5bc851cad33d4995b681c562ae0b83ac/2/aee74c3f33bc525d90253abac02637215627a6b3018259d266f2900c71dc008e?cache_buster=1761042731" target="_blank" rel="noreferrer noopener">early clinical development</a> with Biorasi’s global patient recruitment capabilities to provide biotech and pharma Sponsors with a simplified, efficient pathway from Investigational New Drug (IND) to proof-of-concept (POC) with seamless transitions from healthy volunteers into patient groups within first-in-human (FIH) Phase I/IIa clinical trials.</p> <p>Sponsors will benefit from Quotient Sciences’ clinical pharmacology expertise, with facilities in Miami (US) and Nottingham (UK) comprising 230 beds and supported by a large database of trial participants. This is complemented by Biorasi’s global patient recruitment network, which spans a wide range of therapeutic areas including dermatology, neurology, nephrology, cell therapy, and other specialty fields. </p> <p>The partnership will provide sponsors with a single provider model for FIH to POC programs, with the option of a single contract and a unified protocol and regulatory submissions to reduce the outsourcing complexity and accelerate development timelines. </p> <p>Quotient Sciences is a recognized leader in early clinical development, with deep expertise in Phase I healthy volunteer studies and early patient proof-of-concept (POC) trials. To meet growing industry demand for patient assessments and biomarker integration in first-in-human (FIH) studies, the company is expanding its patient access framework through a network of academic and commercial collaborators. </p> <p>These hybrid or multi-part protocols—combining healthy volunteer and patient cohorts within a single integrated design—offer speed, flexibility, and scientific rigor and a seamless pathway for generating early clinical data.</p> <p>Thierry Van Nieuwenhove, CEO of Quotient Sciences, commented: “This partnership reflects our 35-year commitment to helping customers accelerate drug development to Proof of Concept by reducing complexity and breaking down traditional barriers. By combining Quotient’s clinical expertise with Biorasi’s global patient access network, we enable Sponsors to efficiently conduct early-phase studies under a single operational and contracting model, while maintaining the highest standards of clinical research and data quality. We take your molecule to the next stage of its journey—faster and more cost-effectively than anyone else.”</p> <p>“Biotech and pharma innovators need flexible, reliable solutions to succeed in today’s evolving clinical trial environment,” added Chris O’Brien, CEO of Biorasi. “Through this collaboration with Quotient Sciences, we are providing Sponsors with a simplified, scalable model that supports everything from FIH studies to patient POC, helping new therapies reach patients faster.”</p> <p>The expansion into patients is a natural extension of Translational Pharmaceutics®, Quotient’s disruptive approach to drug development which seamlessly integrates formulation development, drug product manufacturing, and clinical testing, saving up to 12 months and accelerating data-driven decision making. </p> <p>The venture also expands opportunities for adjacent services including comprehensive CDMO offerings such as pharmacy compounding, drug product manufacturing, data sciences, and regulatory support.</p> <p></p> <p><strong>About Quotient Sciences</strong></p> <p><a href="https://tracking.us.nylas.com/l/5bc851cad33d4995b681c562ae0b83ac/3/3fab6f63bf5457f0f78f212b815ff434dc2c971e07c86346ecf5c93b7dbf5350?cache_buster=1761042731" target="_blank" rel="noreferrer noopener">Quotient Sciences</a> is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast, because humanity needs novel therapeutic solutions, fast. Quotient Sciences has been recognised as a multi-year winner of the CRO Leadership Awards in 2021, 2022, and 2024 and of the CDMO Leadership Awards in 2023. For more information, visit <a href="https://tracking.us.nylas.com/l/5bc851cad33d4995b681c562ae0b83ac/4/b66a6cf21a8a88b045c87482df1f07505b02d9b3d6cd8c437f7a9acf2023d6b3?cache_buster=1761042731" target="_blank" rel="noreferrer noopener">quotientsciences.com</a>.</p> <p><strong>About Biorasi</strong><strong><br></strong><a href="https://tracking.us.nylas.com/l/5bc851cad33d4995b681c562ae0b83ac/5/9c643fd3684ba133d02dec3822b9f1f406937e1cd5e06e90b1ecebef55b83150?cache_buster=1761042731" target="_blank" rel="noreferrer noopener">Biorasi</a> is a global clinical research organization (CRO) that delivers speed-to-market strategies for small to midsized biotech and biopharma sponsors. With over two decades of expertise in running clinical trials across dermatology, oncology, neurology, nephrology, and other key therapeutic areas, Biorasi leverages reliable, flexible, and accessible solutions necessary to succeed in today’s dynamic and evolving clinical trials industry. For more information, email: <a href="mailto:info@biorasi.com">info@biorasi.com</a> or (786) 388-0700.</p> <p><strong>For press enquiries, contact:</strong><strong><br></strong>Erica Fearnley<br>Executive Director, Strategic Marketing at Quotient Sciences<br><a href="https://tracking.us.nylas.com/l/5bc851cad33d4995b681c562ae0b83ac/6/80338e13438b6489f01aee231c3451b9d17a569ea999f497278aa5feba651948?cache_buster=1761042731" target="_blank" rel="noreferrer noopener">erica.fearnley@quotientsciences.com</a> </p> <p>Adam Gottlieb<br>Director, Marketing & Communications at Biorasi<br><a href="https://tracking.us.nylas.com/l/5bc851cad33d4995b681c562ae0b83ac/7/3c9c32a368388e05bf32d3e6997ce16fa1f072905804bd6af305d01d86c14b94?cache_buster=1761042731" target="_blank" rel="noreferrer noopener">adam.gottlieb@biorasi.com</a> </p> <p>Rachael Heath<br>Senior PR Manager at ramarketing (on behalf of Quotient Sciences)<br><a href="https://tracking.us.nylas.com/l/5bc851cad33d4995b681c562ae0b83ac/8/6c3a5d6be4f38617f8c0d5c70fdeca14d3ddd4d95764dd1a78f7854e45a7f103?cache_buster=1761042731" target="_blank" rel="noreferrer noopener">rachael@ramarketingpr.com</a></p>]]></content:encoded> </item> <item> <title>Inizio Evoke Launches Cognitev™ to Power Smarter, Faster Decisions Across Life Sciences Commercialization</title> <link>https://international-pharma.com/inizio-evoke-launches-cognitev-to-power-smarter-faster-decisions-across-life-sciences-commercialization/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Fri, 17 Oct 2025 11:38:15 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41740</guid> <description><![CDATA[Inizio Evoke, a leading global health marketing, communications, and transformation partner, today announced the launch of Cognitev™, a proprietary commercial intelligence engine designed to power data-driven creativity and AI-enabled decision-making across the life sciences journey. Defining a New Standard for Commercial Intelligence Built on over 35 million hours of real-world HCP and patient behavioral data, […]]]></description> <content:encoded><![CDATA[<p>Inizio Evoke, a leading global health marketing, communications, and transformation partner, today announced the launch of Cognitev<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />, a proprietary commercial intelligence engine designed to power data-driven creativity and AI-enabled decision-making across the life sciences journey.</p> <p><strong>Defining a New Standard for Commercial Intelligence</strong></p> <p>Built on over 35 million hours of real-world HCP and patient behavioral data, the Cognitev <img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> Data Lake connects proprietary data assets, advanced analytics, and domain expertise into a unified intelligence framework. Designed with the highest standards of data privacy, security, and regulatory compliance, Cognitev<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> ensures insights are both powerful and responsible. By combining real-time behavioral signals with human insight, Cognitev<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> helps brands and teams make smarter, faster decisions – from brand strategy to field optimization and omnichannel engagement. It also connects audience journeys, channels, and performance models – ensuring seamless orchestration across every stage of engagement.</p> <p>“Cognitev<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> is the next evolution of how Inizio Evoke unlocks growth through data-driven insight and human centricity. By bringing together our proprietary behavioral data, advanced technology, and world-class talent, Cognitev<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> empowers our people and our clients with the intelligence to make smarter decisions, achieve stronger commercial results, and deliver more human outcomes.” – Reid Connolly, Founder & CEO</p> <p>Over the past quarter, Cognitev<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> has been embedded across Inizio Evoke’s commercial, creative, and communications business, informing how audiences are segmented, how content is delivered, and how performance is optimized. Cognitev<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> helps uncover how audiences think, behave, and decide – bringing greater clarity to where and how to act. It sharpens strategic precision by turning live behavioral signals into timely guidance, connects journeys and channels across teams, and drives commercial performance by accelerating results and reducing inefficiency across the enterprise. This connected intelligence enables alignment and agility across disciplines – bringing data-led clarity to every corner of the commercialization effort.</p> <p>According to Jamie Avallone, Chief Data Officer at Inizio Evoke, “Cognitev<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> is more than a product; it’s the intelligence that powers how we think, plan, and act. It strengthens every solution we deliver, translating complexity into clarity and driving measurable impact for our clients.”</p> <p><strong>About Inizio Evoke</strong></p> <p>Inizio Evoke is a global health marketing, communications, and transformation platform. Purpose-built to support life sciences companies in their most critical moments, Inizio Evoke harnesses the power of data, creativity, and human connection to drive transformative growth. The company is united by a shared purpose: health more human<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />.<br>Learn more at <a href="https://tracking.us.nylas.com/l/62a5a848a05c447189ba958643c65456/0/2d8c0618648077cf2b98bfb1b397890d06e257ee00cf168e52bf2c9d4f941f21?cache_buster=1760692236" target="_blank" rel="noreferrer noopener">www.inizioevoke.com</a>.</p> <p><strong>About Inizio</strong></p> <p>Inizio is a commercialization partner providing tailored, innovative solutions to help health and life sciences companies across the clinical development and commercialization journey. By simplifying the complex and enhancing outcomes, Inizio helps unlock value at every stage of the asset lifecycle.<br>Learn more at <a href="https://tracking.us.nylas.com/l/62a5a848a05c447189ba958643c65456/1/ae0fdaf51995ecaadf9c06a0c2b7477bc9903c1f97afa38aa3a9978a3c43d6ee?cache_buster=1760692236" target="_blank" rel="noreferrer noopener">www.inizio.com</a>.</p>]]></content:encoded> </item> <item> <title>Orbia Fluor & Energy Materials delivers first ISO tank of low-GWP propellant </title> <link>https://international-pharma.com/orbia-fluor-energy-materials-delivers-first-iso-tank-of-low-gwp-propellant/</link> <dc:creator><![CDATA[Alice Phillips]]></dc:creator> <pubDate>Fri, 17 Oct 2025 10:09:13 +0000</pubDate> <category><![CDATA[News]]></category> <guid isPermaLink="false">https://international-pharma.com/?p=41738</guid> <description><![CDATA[Production milestone marks progress in the scale-up and availability of low-GWP medical propellants   GLOBAL leader in the development, manufacture and supply of fluor based products Orbia Fluor & Energy Materials (Orbia), has announced it has supplied its first large-scale delivery of its new low global warming potential (low-GWP) medical propellant, Zephex® 152a.  An ISO tank containing 17 […]]]></description> <content:encoded><![CDATA[<p><em>Production milestone marks progress in the scale-up and availability of low-GWP medical propellants </em> </p> <p>GLOBAL leader in the development, manufacture and supply of fluor based products <a href="https://5ce0337d.streaklinks.com/CnuEom67-2-z6v7Thgfnb1wW/https%3A%2F%2Fwww.kouraglobal.com%2F" target="_blank" rel="noreferrer noopener">Orbia Fluor & Energy Materials</a> (Orbia), has announced it has supplied its first large-scale delivery of its new low global warming potential (low-GWP) medical propellant, Zephex® 152a. </p> <p>An ISO tank containing 17 tonnes of Zephex® 152a has been delivered to global CDMO and drug delivery specialist Kindeva’s new facility in Loughborough, UK.</p> <p>Compared with traditional propellants, Zephex® 152a can reduce the footprint of the propellant within the MDI by 90%, which translates to around 22,000 tonnes of CO<sub>2</sub> equivalent emissions reduction for this single ISO tank delivery. This equates to around 2-3% of the annual pMDI emissions in the UK*. </p> <p><a href="https://5ce0337d.streaklinks.com/CnuEom-kJOf-zOxGwwKq5q5F/https%3A%2F%2Fwww.kouraglobal.com%2Fkindeva-drug-delivery-and-orbia-fluorinated-solutions-koura-announce-collaboration-for-low-gwp-propellant-conversion%2F" target="_blank" rel="noreferrer noopener">This announcement </a>demonstrates the close collaboration between Orbia and Kindeva in the transition to lower-carbon respiratory treatments for patients worldwide.It comes weeks after Kindeva hosted a ribbon-cutting ceremony for its new UK headquarter and MDI Center of Excellence manufacturing hub at Charnwood Campus Science Innovation and Technology Park in Loughborough. </p> <p>Kindeva will be the first global CDMO to execute a commercial-scale and volume MDI filling line for Zephex® 152a and is targeting to manufacture more than 100 million units per year at the site. </p> <p>Orbia aims to complete its full-scale Zephex® 152a plant towards the end of 2026 which will ensure the commercial supply of large quantities of the low-GWP propellant to its customers and will accelerate the transition to a more sustainable respiratory pharmaceutical industry.</p> <p>The ISO delivered to Kindeva was made possible thanks to the existing small-scale Zephex® 152a plant, also situated in the North West of England. </p> <p>Markus Laubscher, Head of Pharmaceutical Business Unit at Orbia Fluor & Energy Materials, said: “Today’s announcement is a landmark moment, not just for Orbia and Kindeva, but for the entire respiratory pharmaceutical industry. For 30 years our Zephex® medical propellants have set the global standard for high-purity, high performance, and a reliable supply that has met the existing needs of patients worldwide. Our priority is to now accelerate the scale-up of Zephex®152a, which will meet the future needs of our customers and the wider industry, while reducing the environmental impact. </p> <p>“Through these investments, partnership, and our shared commitments, Orbia and Kindeva are putting the UK at the center of the global transition to low-GWP propellants.” </p> <p>Craig Sommerville, Senior Vice President MDI at Kindeva said: “The arrival of the first ISO tank of Zephex® 152a at our new Loughborough facility represents a defining milestone in Kindeva’s mission to accelerate the transition to next-generation propellants. This achievement reflects the power of our collaboration with Orbia. It underscores our unwavering commitment to advancing technologies that both safeguard the environment and deliver dependable treatment options for patients worldwide.</p> <p>“As the first CDMO to manufacture commercial-scale MDIs using Zephex® 152a, we are proud to be leading the charge in creating a more sustainable future for respiratory care.” </p> <p>This year marks the 30th anniversary of the Zephex® brand, which was commemorated at the <a href="https://5ce0337d.streaklinks.com/CnuEom-tbV4INtkkyQQftI7r/https%3A%2F%2Fwww.kouraglobal.com%2Fworlds-most-widely-used-medical-propellant-brand-celebrates-its-30-year-anniversary%2F" target="_blank" rel="noreferrer noopener">Summit event</a> in Rocksavage, Runcorn, on 18 June 2025 with industry partners, including Kindeva. </p> <p></p> <p>About Orbia Fluor & Energy Materials </p> <p>Orbia’s Fluor & Energy Materials business is a global leader in the development, manufacture and supply of fluoroproducts that play a fundamental role in enhancing everyday lives and shortening the path to a sustainable, circular economy. </p> <p>Backed by over 35 years of experience, Orbia F&EM products are used in a vast range of applications, including electric vehicles and energy storage, urban and rural infrastructure, indoor climate management, food and medicine refrigeration, and treating respiratory conditions through development of safe and innovative low-GWP propellants for metered dose inhalers. Orbia has 1,700 employees and eight manufacturing facilities worldwide, serving 60 countries through a global sales and distribution network. </p> <p><a href="http://www.orbia-fem.com/" target="_blank" rel="noreferrer noopener">www.orbia-fem.com</a> </p> <p>About Kindeva </p> <p>At Kindeva, we manufacture more tomorrows for patients worldwide. With best-in-class facilities, and comprehensive CDMO services, we offer more than manufacturing – we deliver strategic value. </p> <p>Our global network of 10 manufacturing and testing sites offers exceptional integrated knowledge and capabilities, including Annex 1-compliant state-of-the art aseptic fill finish capacity, and next generation sustainable inhalation propellant technology. </p> <p>By combining expertise in injectable, pulmonary, nasal and dermal drug delivery, we help meet the demands of today and deliver the possibilities of tomorrow. </p> <p><a href="http://www.kindevadd.com/" target="_blank" rel="noreferrer noopener">www.kindevadd.com</a> </p>]]></content:encoded> </item> </channel></rss> If you would like to create a banner that links to this page (i.e. this validation result), do the following:
Download the "valid RSS" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):
If you would like to create a text link instead, here is the URL you can use:
http://www.feedvalidator.org/check.cgi?url=https%3A//international-pharma.com/feed/
